TAXUS Clinical Data as the Foundation for Expanded Indications
The positive TAXUS IV data bodes well for future applications of drug-eluting stent technology. We believe that as more clinical data becomes available, the TAXUS system will drive an expansion of the drug-eluting stent market, offering further evidence that the TAXUS system is safe and effective as a device for treatment of particular segments of the coronary disease market (possible segments include patients with longer lesions, in-stent restenosis, left main disease, multi-vessel, bifurcated and large vessel lesions, and acute myocardial infarction). Expansion into new indications may also allow this device to be used in other parts of the vasculature, such as renal arteries and lower leg vessels. Boston Scientific’s Clinical Sciences team will continue to work aggressively to pursue expanded indications for the TAXUS system.

Boston Scientific is also conducting post-market registries to monitor and analyze “real world” results associated with the use of the TAXUS system in approximately 5,000 patients, with hopes to include an additional 5,000. These registries include the multinational WISDOM and MILESTONE II registries, and the U.S.-based ARRIVE registry. In addition, plans are underway for new clinical trials using the Liberté stent, the platform for our next-generation drug-eluting stent system.